Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 12:56 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 2,347 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Intravenous Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ELA026 in Single and Multiple Doses in Healthy Volunteers

NCT05556863
View directory record Official record
Conditions
Healthy Volunteers
Interventions
ELA026
Drug
Lead sponsor
Electra Therapeutics Inc.
Industry
Eligibility
19 Years to 60 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 3 Interventional

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

NCT00789633
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Masitinib, Placebo, Gemcitabine
Drug
Lead sponsor
AB Science
Industry
Eligibility
18 Years and older
Enrollment
353 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Norwich, Connecticut • Orlando, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2018 · Synced Oct 17, 2026, 12:56 AM EDT
Active, not recruiting Phase 3 Interventional Results available

A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

NCT06298552
View directory record Official record
Conditions
Generalized Myasthenia Gravis, gMG, Myasthenia Gravis, Generalized, Myasthenia Gravis
Interventions
Efgartigimod IV, Placebo IV
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
19
States / cities
Scottsdale, Arizona • Fresno, California • Boca Raton, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 17, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional Results available

STRIDE - STimulating Immune Response In aDvanced brEast Cancer

NCT00925548
View directory record Official record
Conditions
Breast Cancer
Interventions
Tecemotide (L-BLP25) and Hormonal Treatment, Placebo of tecemotide (L-BLP25) and Hormonal Treatment, cyclophosphamide, sodium chloride (NaCl)
Biological · Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Hickory, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms

NCT02043678
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Radium-223 dichloride (Xofigo, BAY88-8223), Matching placebo (normal saline), Abiraterone, Prednisone/Prednisolone
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older · Male only
Enrollment
806 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
29
States / cities
Anchorage, Alaska • Tucson, Arizona • Oceanside, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics

NCT03162250
View directory record Official record
Conditions
Bacteremia
Interventions
DSTA4637S, Placebo, SOC
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Torrance, California • Detroit, Michigan • Royal Oak, Michigan + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 1 Interventional

End-stage Renal Disease (ESRD) Pilot Study

NCT03787368
View directory record Official record
Conditions
Renal Dialysis
Interventions
BAY1213790, 0.9% sodium chloride solution
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 80 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Chula Vista, California • Bradenton, Florida • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Preoperative Antithrombin Supplementation in Patients Undergoing High-Risk Cardiopulmonary Bypass

NCT02037555
View directory record Official record
Conditions
Cardiac Surgery, Cardiopulmonary Bypass
Interventions
AT-III (Human), Placebo
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years and older
Enrollment
425 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
41
States / cities
Orange, California • San Francisco, California • Stanford, California + 36 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 17, 2026, 12:56 AM EDT
Not listed Phase 2 Interventional

Study to Improve Renal Function After Kidney Transplantation

NCT01286727
View directory record Official record
Conditions
Delayed Graft Function
Interventions
BB3
Drug
Lead sponsor
Angion Biomedica Corp
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
6
States / cities
San Diego, California • Washington D.C., District of Columbia • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2015 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Magnesium vs Placebo for Tonsillectomy

NCT02218424
View directory record Official record
Conditions
Pain
Interventions
Magnesium, Normal saline
Drug
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
4 Years to 10 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 3, 2019 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of MEDI4893

NCT02296320
View directory record Official record
Conditions
Staphylococcus Aureus Pneumonia
Interventions
MEDI4893, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 17, 2026, 12:56 AM EDT
Terminated Phase 4 Interventional Results available

Fentanyl for Breakthrough Pain in the Emergency Department

NCT01812759
View directory record Official record
Conditions
Pain
Interventions
Fentanyl Nasal Spray, Hydromorphone PCA, Placebo Nasal Spray
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)

NCT03788967
View directory record Official record
Conditions
Complicated Urinary Tract Infection, Acute Pyelonephritis
Interventions
TBPM-PI-HBr, Ertapenem, Dummy Infusion, Dummy tablets
Drug
Lead sponsor
Spero Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
La Mesa, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3BNC117 and 10-1074 in HIV Uninfected Adults

NCT02824536
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117, 10-1074, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19

NCT04315298
View directory record Official record
Conditions
COVID-19
Interventions
Sarilumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,912 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
62
States / cities
Los Angeles, California • Sacramento, California • Santa Monica, California + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2021 · Synced Oct 17, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

PROPER Trial of Pain and Inflammation After Knee Arthroscopy

NCT05149287
View directory record Official record
Conditions
Meniscus Tear, Meniscus Lesion, Cartilage Injury
Interventions
Ceftriaxone, Placebo
Drug · Other
Lead sponsor
Austin V Stone
Other
Eligibility
18 Years to 55 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 5, 2023 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

NCT03142334
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
Pembrolizumab, Placebo
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
994 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
62
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

3BNC117-LS First-in-Human Phase 1 Study

NCT03254277
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
3BNC117-LS, Placebo
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 65 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 17, 2026, 12:56 AM EDT
Completed Phase 2 Interventional Results available

An Efficacy and Safety Study of Intetumumab (CNTO 95) in Participants With Metastatic Hormone Refractory Prostate Cancer

NCT00537381
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Docetaxel, Prednisone, Intetumumab, Placebo
Drug · Biological
Lead sponsor
Centocor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
7
States / cities
Birmingham, Alabama • Los Angeles, California • San Bernardino, California + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Oct 17, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional Results available

An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy (PSP)

NCT03391765
View directory record Official record
Conditions
Progressive Supranuclear Palsy (PSP)
Interventions
ABBV-8E12, Placebo solution for IV infusion on Day 15
Drug
Lead sponsor
AbbVie
Industry
Eligibility
40 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
24
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 17, 2026, 12:56 AM EDT
Terminated Phase 3 Interventional

A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)

NCT05263999
View directory record Official record
Conditions
Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD, aGVHD
Interventions
Itolizumab, EQ001 Placebo
Biological · Drug
Lead sponsor
Equillium
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
38
States / cities
Birmingham, Alabama • Duarte, California • La Jolla, California + 31 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 17, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer

NCT00738699
View directory record Official record
Conditions
Ovarian Cancer
Interventions
MORAb-003 (farletuzumab), 0.9% Saline, Paclitaxel
Drug
Lead sponsor
Morphotek
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
415 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
34
States / cities
Mobile, Alabama • Phoenix, Arizona • Greenbrae, California + 29 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2017 · Synced Oct 17, 2026, 12:56 AM EDT
Terminated Phase 2 Interventional

Paclitaxel for the Treatment of Upper-Extremity Arteriovenous Access Fistula Stenosis

NCT01868984
View directory record Official record
Conditions
Fistula Stenosis
Interventions
Paclitaxel, Standard Therapy
Drug · Procedure
Lead sponsor
Englewood Hospital and Medical Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Englewood, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 12, 2020 · Synced Oct 17, 2026, 12:56 AM EDT